carmustine has been researched along with Carcinoma in 24 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 8.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "A selected case file of 32 patients with carcinoma of the lung which had passed the stage of surgical cure was randomized in 3 arms and treated with different schedules: regimen A, adriamycin plus cyclophosphamide; regimen B, the BACON combination, slightly modified; regimen CVP, cyclophosphamide plus vincristine plus prednisone." | 5.04 | Combined chemotherapy for unresectable carcinoma of the lung: a randomized trial. ( Arosio, A; Burdick, L; Cunietti, E; Eridani, S; Maggio, L; Periti, M; Perrone, G, 1978) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 4.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| " The chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), carboplatin, and camptothecin were incorporated into controlled-release polymers and tested individually against intracranial challenges with one of four tumors (lung carcinoma, renal cell carcinoma, colon carcinoma, and melanoma)." | 3.69 | Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. ( Anderson, RC; Babel, KM; Brat, DJ; Brem, H; Ewend, MG; Pinn, ML; Tabassi, K; Tyler, BM; Williams, JA, 1996) |
| "Prostate carcinoma is the most commonly occurring malignancy in men." | 1.32 | 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways. ( Do, P; Huynh, H; Nguyen, TH; Panasci, L, 2004) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| "AC = adriamycin and cyclophosphamide in ovarian cancer." | 1.27 | Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide. ( Amunni, G; Bonazza, M; Branconi, F; Massi, GB; Mazzei, T; Scarselli, G, 1984) |
| "In nine of 11 (82%) instances, tumors were sensitive to a particular drug, and the patient had at least 50% regression of tumor following treatment with the tested drug." | 1.26 | Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study. ( Burk, MW; Campbell, MA; Giuliano, AE; Kaiser, LR; Kern, DH; Mann, BD; Morton, DL, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (58.33) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montgomery, JA | 1 |
| McCaleb, GS | 1 |
| Johnston, TP | 2 |
| Mayo, JG | 2 |
| Laster, WR | 2 |
| McCormack, A | 1 |
| Dekkers, OM | 1 |
| Petersenn, S | 1 |
| Popovic, V | 1 |
| Trouillas, J | 1 |
| Raverot, G | 1 |
| Burman, P | 1 |
| PROPST, A | 1 |
| Huynh, H | 2 |
| Nguyen, TH | 2 |
| Panasci, L | 2 |
| Do, P | 1 |
| Ong, CK | 1 |
| Wong, E | 1 |
| Leong, CT | 1 |
| Pisarev, MA | 1 |
| Dagrosa, MA | 1 |
| Thomasz, L | 1 |
| Juvenal, G | 1 |
| Mann, BD | 1 |
| Kern, DH | 1 |
| Giuliano, AE | 1 |
| Burk, MW | 1 |
| Campbell, MA | 1 |
| Kaiser, LR | 1 |
| Morton, DL | 1 |
| deKernion, JB | 1 |
| Lindner, A | 1 |
| Mazzei, T | 1 |
| Bonazza, M | 1 |
| Amunni, G | 1 |
| Scarselli, G | 1 |
| Branconi, F | 1 |
| Massi, GB | 1 |
| Yamashita, T | 1 |
| Watanabe, M | 1 |
| Onodera, M | 1 |
| Shimaoka, K | 1 |
| Ito, K | 1 |
| Fujimoto, Y | 1 |
| Itoyama, S | 1 |
| Sugawara, I | 1 |
| Ewend, MG | 1 |
| Williams, JA | 1 |
| Tabassi, K | 1 |
| Tyler, BM | 1 |
| Babel, KM | 1 |
| Anderson, RC | 1 |
| Pinn, ML | 1 |
| Brat, DJ | 1 |
| Brem, H | 1 |
| Eridani, S | 1 |
| Burdick, L | 1 |
| Maggio, L | 1 |
| Cunietti, E | 1 |
| Periti, M | 1 |
| Arosio, A | 1 |
| Perrone, G | 1 |
| Spitzer, G | 1 |
| Dicke, KA | 1 |
| Verma, DS | 1 |
| Zander, A | 1 |
| McCredie, KB | 1 |
| Posner, JB | 1 |
| Shapiro, WR | 1 |
| Kanj, SS | 1 |
| Sharara, AI | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Peters, WP | 2 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Toso, S | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 1 |
| Villar-Grimalt, A | 1 |
| Candel, MT | 1 |
| Delgado, F | 1 |
| García-Reinoso, J | 1 |
| Sanchis, C | 1 |
| Viciano, V | 1 |
| Asencio, F | 1 |
| Martínez-Abad, M | 1 |
| Aguilo, J | 1 |
| Sánchez, JJ | 1 |
| Ushio, Y | 1 |
| Arita, N | 1 |
| Hayakawa, T | 1 |
| Mogami, H | 1 |
| Hasegawa, H | 1 |
| Bitoh, S | 1 |
| Oku, Y | 1 |
| Ikeda, H | 1 |
| Kanai, N | 1 |
| Kanoh, M | 1 |
| Schoen, HD | 1 |
| Wendt, T | 1 |
| Eder, JP | 1 |
| Henner, WD | 1 |
| Schryber, S | 1 |
| Wilmore, D | 1 |
| Finberg, R | 1 |
| Schoenfeld, D | 1 |
| Bast, R | 1 |
| Gargone, B | 1 |
| Antman, K | 1 |
| Facchini, V | 1 |
| Gadducci, A | 1 |
| Bogi, G | 1 |
| Colombi, L | 1 |
| Basile, AG | 1 |
| Ballantini, M | 1 |
| De Pasquale, F | 1 |
| Fioretti, P | 1 |
| Carter, SK | 2 |
| Schabel, FM | 2 |
| Broder, LE | 1 |
| Andrews, CM | 1 |
5 reviews available for carmustine and Carcinoma
| Article | Year |
|---|---|
[Boron neutron capture therapy applied to undifferentiated thyroid carcinoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Colorectal Neopl | 1991 |
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
4 trials available for carmustine and Carcinoma
| Article | Year |
|---|---|
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Combined chemotherapy for unresectable carcinoma of the lung: a randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Small Cell; Carmustine; Cycloph | 1978 |
Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Carcinom | 1991 |
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cell-Free System; | 1972 |
17 other studies available for carmustine and Carcinoma
| Article | Year |
|---|---|
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
Topics: Animals; Carcinoma; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimen | 1977 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
[Morphological findings after moving beam irradiation of esophagus carcinoma].
Topics: Carcinoma; Carmustine; Esophageal Neoplasms; Etoposide; Humans; Radiotherapy | 1957 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Cycle; Cell Cycle Proteins; Cell Divisio | 2004 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carmustine; Caspase 3; Casp | 2005 |
Clinical correlations with drug sensitivities in the clonogenic assay: a retrospective study.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Hepatocellular; Carmustine; Cell Division; D | 1982 |
Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; | 1984 |
Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transp | 1994 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcin | 1996 |
High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
Topics: Adult; Aged; Bone Marrow Transplantation; Carcinoma; Carmustine; Female; Freezing; Humans; Male; Mel | 1979 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
Myocardial ischemia associated with high-dose carmustine infusion.
Topics: Adult; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1991 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 1986 |
Polychemotherapy with carmustine, cyclophosphamide plus adriamycin in the treatment of advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; | 1985 |
Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cyclohexanes; Cyclophosphamide; Lu | 1972 |